| 04:29 | Merck & Co.'s Endometrial Cancer Combo Extends Progression-free Survival in Late-stage .. |  |
| 03.02. | Nueva alerta de compra en la cartera Inversor EE.UU. |  |
| 03.02. | Alert: New purchase in the USA Investor Portfolio | |
| 03.02. | Alerte Nouvel Achat dans le portefeuille Investisseur USA |  |
| 03.02. | Merck : un traitement a atteint le critère principal de survie | |
| 03.02. | Merck Says Trial of Keytruda and Chemotherapy to Treat Endometrial Cancer Meets Primary.. | |
| 03.02. | Merck's Keytruda Meets Main Endpoints in Endometrial Carcinoma Study | |
| 03.02. | Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression.. | |
| 03.02. | Merck Announces Phase 3 NRG-GY018 Trial Evaluating Keytrudav | |
| 03.02. | Merck & Co. Flags Lower COVID-19 Drug Sales in FY23 | |
| 02.02. | Prospects of Fed's Rate-Hiking Cycle Ending Soon Lifts Equities | |
| 02.02. | Global markets live: ABB, Infineon, Shell, Metlife, Boeing... | |
| 02.02. | Merck Posts Mixed Fourth-Quarter Results, Issues Downbeat Full-Year Earnings Outlook | |
| 02.02. | Merck sets 2023 earnings expectations below Street forecasts | |
| 02.02. | No-surprise rate hikes | |
| 02.02. | Sector Update: Health Care Stocks Mixed Pre-Bell Thursday | |
| 02.02. | Les valeurs à suivre aujourd'hui à Wall Street - Jeudi 2 février 2023 | |
| 02.02. | Merck : performant au quatrième trimestre 2022 mais chute sur les prévisions de BP.. | |
| 02.02. | Merck fait mieux que prévu au 4ème trimestre | |
| 02.02. | Merck Q4 Adjusted Earnings Slip, Sales Increase; Issues 2023 Outlook | |
| 02.02. | Merck : 4Q22 Merck Earnings Presentation | |
| 02.02. | Merck : hausse de 22% des ventes sur l'année 2022 | |
| 02.02. | Merck : Q4 Earnings Snapshot | |
| 02.02. | Merck & Co., Inc. Provides Earnings Guidance for the Year 2023 | |
| 02.02. | GUIDANCE: (MRK) MERCK & CO. Expects Fiscal Year 2023 Revenue Range $57.2B - $58.. | |
| 02.02. | GUIDANCE: (MRK) MERCK & CO. Expects Fiscal Year 2023 EPS Range $6.80 - $6.95 | |
| 02.02. | Earnings Flash (MRK) MERCK & CO. Reports Q4 Revenue $13.83B | |
| 02.02. | Earnings Flash (MRK) MERCK & CO. Posts Q4 EPS $1.62 | |
| 02.02. | Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results | |
| 02.02. | Bolsa de Madrid: Powell, está confuso | |
| 02.02. | En Direct des Marchés : BNP Paribas, Orange, Dassault Systèmes, Pu.. | |
| 02.02. | Powell, c'est flou | |
| 02.02. | Merck & Co. Says No Direct Evidence of COVID-19 Pill Leading to New Variants | |
| 30.01. | AstraZeneca Doses First Patient in Phase 3 Study of Datopotamab Deruxtecan to Treat Lun.. | |
| 30.01. | Daiichi begins Tropion-Lung07 phase 3 trial for lung cancer treatment | |
| 30.01. | Merck - FDA Approves KEYTRUDA as Adjuvant Treatment Following Surgical Resection and Pl.. | |
| 27.01. | Merck : la FDA approuve une nouvelle indication du Keytruda | |
| 27.01. | Merck Says Keytruda Approved by FDA as Adjuvant Treatment for Non-Small Cell Lung Cance.. | |
| 27.01. | FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resecti.. | |
| 27.01. | Merck Announces the U.S. Food and Drug Administration has Approved KEYTRUDA | |
| 27.01. | Merck & Co.'s Animal Health Unit Wins US FDA Nod for Expanded Use of Flea Drug for Dogs | |
| 26.01. | Merck : a reçu une approbation de la FDA pour BRAVECTO | |
| 26.01. | Merck Animal Health Division Says US FDA Approves Expanded Indication of Bravecto Chews.. | |
| 26.01. | Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO (flu.. | |
| 26.01. | Merck & Co.'s Keytruda Combo Prolongs Survival in Late-stage Biliary Tract Cancer Study | |
| 25.01. | Merck : essai non-concluant dans le cancer de la prostate | |
| 25.01. | Merck : Keytruda prometteur dans le cancer des voies biliaires | |
| 25.01. | Merck to Cease Phase 3 Trial for Treatment of Prostate Cancer Due to Failure in Meeting.. | |
| 25.01. | Merck Reports Keytruda Phase 3 Success, Failure | |
| 25.01. | Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamid.. | |
| 25.01. | Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamid.. | |
| 25.01. | Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Surv.. | |
| 25.01. | Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall.. | |
| 24.01. | Merck & Company Keeps Quarterly Dividend at $0.73 a Share; Payable April 10 to Holders .. | |
| 24.01. | Merck Announces Second-Quarter 2023 Dividend | |
| 24.01. | Merck Announces Dividend for the Second-Quarter of 2023 , Payable on April 10, 2023 | |
| 24.01. | Merck : Provides Update on Expenses Related to Recent Transactions | |
| 23.01. | Genexine Receives Fast Track Designation from Korean Health Authority (MFDS) for its pr.. | |
| 19.01. | Evaxion Biotech Says Cancer Immunotherapy Candidate EVX-01, With Keytruda, Gets US FDA .. | |
| 18.01. | Asher Bio Announces Dosing of First Patient in Phase 1a/1b Clinical Trial of AB248, a C.. | |
| 18.01. | Teon Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate Tt-816,.. | |
| 18.01. | Merck Picks Perceiv AI, Other Eight Biomedical Startups for Digital Technologies Progra.. | |
| 18.01. | Merck & Co. Aims To End Presence Of Potential Carcinogen In Diabetes Drugs By End-2023 | |
| 18.01. | Merck Selects Perceiv AI for Inaugural Digital Sciences Studio Cohort | |
| 18.01. | Merck Selects Perceiv AI for Inaugural Digital Sciences Studio Cohort | |
| 17.01. | Merck & Company Reportedly Can Remove Cancer-Causing Nitrosamines From Diabetes Drugs b.. | |
| 17.01. | Microsoft expands access to OpenAI tools, M&S inves.. | |
| 16.01. | Anglia Ruskin University Aru : The science behind the new mRNA cancer vaccines | |
| 16.01. | PFIZER, MERCK : vers des transactions d'ampleur ? | |
| 16.01. | The end of the 60/40 structure in portfolio managem.. | |
| 16.01. | Cronache di Borsa - Lunedì 16 gennaio |  |
| 16.01. | Crédit Suisse licencie, Bayer réoriente, Ford veut .. | |
| 16.01. | Merck Named One of America's Most JUST Companies by JUST Capital and CNBC, Industry Lea.. | |
| 13.01. | Cancer Vaccine Trials Could Start in the in Autumn - UK Signs Deal With Biontech | |
| 12.01. | Health Rounds: Artificial pancreas closer for type 2 diabetes | |
| 12.01. | Merck Completes Tender Offer to Acquire Imago BioSciences, Inc | |
| 11.01. | Insider Sell: Merck | |
| 11.01. | Global markets live: Darktrace, Boeing, Tesla, Wells Fargo, Accentur.. | |
| 11.01. | The bulls are back in town | |
| 11.01. | Merck Vows to Sue Unauthorized COVID Drug Distributors in China | |
| 11.01. | Merck Named One of America's Most JUST Companies by JUST Capital and CNBC Industry Lead.. | |
| 11.01. | Merck & Company Concludes Cash Tender Offer to Acquire Imago BioSciences | |
| 11.01. | Merck : les résultats de l'offre sur Imago BioSciences | |
| 11.01. | Merck & Co. to Launch Legal Battle Against Unauthorized Chinese COVID-19 Drug Sellers | |
| 11.01. | Merck Completes Tender Offer to Acquire Imago BioSciences, Inc. | |
| 11.01. | Merck & Co. Said to Refuse China's Demand to Lower COVID-19 Drug Price | |
| 10.01. | Merck Named One of America's Most JUST Companies by JUST Capital and CNBC, Industry Lea.. | |
| 09.01. | Nabriva Therapeutics Provides Corporate Update | |
| 06.01. | Nabriva Therapeutics Approves Wind-Down Plan, Will Terminate All Non-Essential Employee.. | |
| 05.01. | Triumvira Immunologics Establishes Collaboration with Merck to Evaluate Tac01-Her2 Cell.. | |
| 05.01. | Merck to Hold Fourth-Quarter and Full-Year 2022 Sales and Earnings Conference Call Febr.. | |
| 05.01. | Nouscom Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluat.. | |
| 04.01. | Sector Update: Health Care Stocks Struggle for Direction on Wednesday | |
| 04.01. | Sector Update: Health Care Stocks Mostly Higher in Recent Trading | |
| 04.01. | Global markets live: Microsoft, Nvidia, Cisco, Salesforce, Rivian... | |
| 04.01. | Immutep Enrolls 50% of Patients in Phase 2b Trial for Head, Neck Cancer Treatment | |
| 04.01. | Merck : BofA relève son opinion | |
| 03.01. | Merck to Present at the 41st Annual J.P. Morgan Healthcare Conference | |
| 2022 | Trending : Merck's Molnupiravir Approved for Emergency Use in China | |
| 2022 | Merck's COVID-19 Treatment Molnupiravir Approved for Emergy Use in China | |
Google
Twitter
Facebook
Apple
English (USA)
English (UK)
English (Canada)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Bericht
